GAIA’s Prostana® Reports Positive Signs from Both Urologists and Patients in an Interim Analysis
Hamburg, Friday 22 March 2019 16.00 CEST
GAIA’s Prostana® Reports Positive Signs from Both Urologists and Patients in an Interim Analysis
Prostate cancer is one of the most common cancers in men worldwide. In Germany, it is even the most common cancer in men. In recent years an increase in psychological stress on patients with this disease has also been observed. In order to lessen the psychological strains in these patients, it is critical to offer therapy options and initiate appropriate therapy as soon as possible after the diagnosis.
To alleviate this problem, GAIA has developed, Prostana®, a new fully-automated, patient-centric support system aimed to empower men with prostate cancer. Prostana® is a CE-marked medical device developed by experts in medicine, clinical psychology and psychotherapy. Like all of GAIA’s programs, Prostana® is highly individualized in order to interactively educate patients and their family members about the disease and the different treatment options.
The Institute for Applied Care Research (INAV), who is currently running a study on the Prostana® program, recently released an interim analysis of their evaluation. Initial reports show positive signals regarding all three end points, including satisfaction with therapy decision and confidence in therapy decision. In addition, urologists participating in the study are reporting feeling relieved of their work and seeing better informed patients due to Prostana®. Patients in the study also appear to be very happy with the program – reporting astonishingly positive ratings: 90% are either satisfied or very satisfied with the program, 94% find the information regarding diagnoses and results helpful and 97% find the therapy approach helpful.
Learn more about Prostana® here: http://www.prostana.de/
